| 股票 | 申万二级 | PE | 前瞻PE | PEG | PB | 股息率 | 分红率 | 毛利率 | 固定资产 | 债/EBITDA | FCF/市值 | 营收3年 | 去年 | YTD | 近一年 | 回撤 | 波动 | 市值亿 ▾ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 云南白药 000538 | 中药Ⅱ | 17.4 | 16.4 | 2.05 | 2.22 | 5.1% | 90% | 27% | 8% | 0.1 | 4.7% | +4% | -2% | -8% | -8% | -18% | 14% | 910 |
| 白云山 600332 | 中药Ⅱ | 12.8 | 10.6 | 1.77 | 0.84 | 4.2% | 46% | 19% | 9% | 5.0 | 5.0% | +3% | -7% | -20% | -24% | -27% | 17% | 329 |
| 东阿阿胶 000423 | 中药Ⅱ | 17.4 | 15.8 | 1.13 | 3.06 | 5.7% | 100% | 70% | 15% | 0.0 | 3.6% | +18% | -19% | +5% | +0% | -23% | 24% | 311 |
| 达仁堂 600329 | 中药Ⅱ | 32.7 | 25.5 | 1.50 | 4.66 | 13.3% | 100% | 44% | 10% | 0.1 | 2.5% | -16% | +65% | -12% | -12% | -27% | 32% | 277 |
| 以岭药业 002603 | 中药Ⅱ | 19.3 | 17.6 | 1.10 | 2.43 | 5.0% | 70% | 64% | 48% | 0.0 | 7.0% | -14% | +9% | -4% | +2% | -29% | 34% | 265 |
| 步长制药 603858 | 中药Ⅱ | 66.5 | — | — | 1.56 | 3.8% | 105% | 68% | 24% | 2.5 | 2.2% | -7% | +2% | -4% | -20% | -27% | 27% | 157 |
| 康恩贝 600572 | 中药Ⅱ | 22.4 | 18.3 | 0.87 | 1.58 | 3.4% | 79% | 58% | 27% | 0.1 | 8.7% | +3% | -1% | +2% | -3% | -19% | 26% | 111 |
| 九芝堂 000989 | 中药Ⅱ | 23.2 | 25.2 | 1.26 | 2.08 | 3.3% | 115% | 59% | 22% | 0.1 | 8.1% | -10% | +14% | +6% | -28% | -37% | 34% | 76 |
| 桂林三金 002275 | 中药Ⅱ | 17.8 | 15.8 | 1.58 | 2.22 | 4.0% | 68% | 73% | 26% | 0.5 | 6.4% | +1% | -3% | -10% | -18% | -20% | 21% | 73 |
| 汉森制药 002412 | 中药Ⅱ | 20.6 | — | — | 2.08 | 3.1% | 76% | 73% | 18% | 0.0 | 3.6% | +4% | +7% | +58% | +45% | -31% | 49% | 49 |
| 方盛制药 603998 | 中药Ⅱ | 14.2 | 13.0 | 0.65 | 2.67 | 4.2% | 64% | 68% | 36% | 0.7 | 9.1% | -1% | +13% | -1% | -11% | -30% | 33% | 47 |
| 亚宝药业 600351 | 中药Ⅱ | 14.3 | — | — | 1.63 | 8.3% | 76% | 56% | 31% | 0.1 | 12.3% | -6% | +13% | +12% | -2% | -18% | 28% | 46 |
| 沃华医药 002107 | 中药Ⅱ | 33.2 | — | — | 5.57 | 3.9% | 203% | 75% | 33% | 0.0 | 3.4% | -7% | +36% | +14% | +3% | -31% | 44% | 39 |
点表头排序。市值单位亿元;去年/YTD 为前复权涨幅;债/EBITDA = 有息负债 ÷ EBITDA。